BetterLife Pharma Inc. announced that Dr. Eleanor Fish will continue to play a key role as part of the company's Scientific Advisory Board after having been appointed, in recognition of her expertise in infectious diseases, to the Canadian Government's COVID-19 Task Force. Dr. Fish is a world-renowned and accomplished scientist with a focus on interferon activity against a variety of viruses including SARS-CoV-2, SARS, Ebola and Zika. Dr. Fish will continue to guide the Company's current and future clinical programs including its research and development strategy for AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation as a possible therapeutic against COVID-19.